nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—CYP2D6—Niacin—atherosclerosis	0.0715	0.3	CbGbCtD
L-DOPA—CYP2D6—Simvastatin—atherosclerosis	0.0565	0.237	CbGbCtD
L-DOPA—CYP2D6—Pravastatin—atherosclerosis	0.0553	0.232	CbGbCtD
L-DOPA—CYP2D6—Lovastatin—atherosclerosis	0.0553	0.232	CbGbCtD
L-DOPA—Mimosine—CCL2—atherosclerosis	0.00626	0.342	CrCbGaD
L-DOPA—Masoprocol—ALOX5—atherosclerosis	0.00246	0.134	CrCbGaD
L-DOPA—Aminosalicylic Acid—ALOX5—atherosclerosis	0.00229	0.125	CrCbGaD
L-DOPA—Mesalazine—ALOX5—atherosclerosis	0.00179	0.098	CrCbGaD
L-DOPA—Flatulence—Rosuvastatin—atherosclerosis	0.00161	0.00347	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Pravastatin—atherosclerosis	0.00156	0.00336	CcSEcCtD
L-DOPA—Weight increased—Pravastatin—atherosclerosis	0.00153	0.00329	CcSEcCtD
L-DOPA—Weight decreased—Pravastatin—atherosclerosis	0.00152	0.00327	CcSEcCtD
L-DOPA—Depression—Pravastatin—atherosclerosis	0.0015	0.00322	CcSEcCtD
L-DOPA—Angioedema—Rosuvastatin—atherosclerosis	0.00149	0.00322	CcSEcCtD
L-DOPA—Acute coronary syndrome—Pravastatin—atherosclerosis	0.00148	0.00318	CcSEcCtD
L-DOPA—Flushing—Lovastatin—atherosclerosis	0.00148	0.00318	CcSEcCtD
L-DOPA—Aminosalicylic Acid—MPO—atherosclerosis	0.00147	0.0805	CrCbGaD
L-DOPA—Neuropathy peripheral—Pravastatin—atherosclerosis	0.00147	0.00316	CcSEcCtD
L-DOPA—Myocardial infarction—Pravastatin—atherosclerosis	0.00147	0.00316	CcSEcCtD
L-DOPA—Urinary tract infection—Pravastatin—atherosclerosis	0.00146	0.00314	CcSEcCtD
L-DOPA—Flushing—Ezetimibe—atherosclerosis	0.00145	0.00312	CcSEcCtD
L-DOPA—Cough—Rosuvastatin—atherosclerosis	0.00143	0.00307	CcSEcCtD
L-DOPA—Alopecia—Lovastatin—atherosclerosis	0.00141	0.00303	CcSEcCtD
L-DOPA—Flushing—Simvastatin—atherosclerosis	0.00138	0.00297	CcSEcCtD
L-DOPA—Alopecia—Ezetimibe—atherosclerosis	0.00138	0.00297	CcSEcCtD
L-DOPA—Haemoglobin—Niacin—atherosclerosis	0.00137	0.00296	CcSEcCtD
L-DOPA—Rhinitis—Niacin—atherosclerosis	0.00137	0.00295	CcSEcCtD
L-DOPA—Mental disorder—Ezetimibe—atherosclerosis	0.00137	0.00294	CcSEcCtD
L-DOPA—Haemorrhage—Niacin—atherosclerosis	0.00137	0.00294	CcSEcCtD
L-DOPA—Flatulence—Lovastatin—atherosclerosis	0.00137	0.00294	CcSEcCtD
L-DOPA—Hypoaesthesia—Niacin—atherosclerosis	0.00136	0.00293	CcSEcCtD
L-DOPA—Dysgeusia—Lovastatin—atherosclerosis	0.00136	0.00292	CcSEcCtD
L-DOPA—Rhinitis—Pravastatin—atherosclerosis	0.00135	0.0029	CcSEcCtD
L-DOPA—Confusional state—Rosuvastatin—atherosclerosis	0.00135	0.0029	CcSEcCtD
L-DOPA—Back pain—Lovastatin—atherosclerosis	0.00134	0.00288	CcSEcCtD
L-DOPA—Hypoaesthesia—Pravastatin—atherosclerosis	0.00134	0.00288	CcSEcCtD
L-DOPA—Flatulence—Ezetimibe—atherosclerosis	0.00134	0.00288	CcSEcCtD
L-DOPA—Muscle spasms—Lovastatin—atherosclerosis	0.00133	0.00287	CcSEcCtD
L-DOPA—Alopecia—Simvastatin—atherosclerosis	0.00132	0.00283	CcSEcCtD
L-DOPA—Back pain—Ezetimibe—atherosclerosis	0.00132	0.00283	CcSEcCtD
L-DOPA—Muscle spasms—Ezetimibe—atherosclerosis	0.00131	0.00281	CcSEcCtD
L-DOPA—Thrombocytopenia—Rosuvastatin—atherosclerosis	0.00131	0.00281	CcSEcCtD
L-DOPA—Vision blurred—Lovastatin—atherosclerosis	0.00131	0.00281	CcSEcCtD
L-DOPA—Mental disorder—Simvastatin—atherosclerosis	0.0013	0.00281	CcSEcCtD
L-DOPA—Tremor—Lovastatin—atherosclerosis	0.0013	0.00279	CcSEcCtD
L-DOPA—Ill-defined disorder—Lovastatin—atherosclerosis	0.00129	0.00277	CcSEcCtD
L-DOPA—Flatulence—Simvastatin—atherosclerosis	0.00128	0.00275	CcSEcCtD
L-DOPA—Dysgeusia—Simvastatin—atherosclerosis	0.00127	0.00273	CcSEcCtD
L-DOPA—Flushing—Niacin—atherosclerosis	0.00127	0.00273	CcSEcCtD
L-DOPA—Angioedema—Lovastatin—atherosclerosis	0.00127	0.00273	CcSEcCtD
L-DOPA—Ill-defined disorder—Ezetimibe—atherosclerosis	0.00126	0.00271	CcSEcCtD
L-DOPA—Anaemia—Ezetimibe—atherosclerosis	0.00126	0.0027	CcSEcCtD
L-DOPA—Malaise—Lovastatin—atherosclerosis	0.00125	0.00269	CcSEcCtD
L-DOPA—Flushing—Pravastatin—atherosclerosis	0.00125	0.00269	CcSEcCtD
L-DOPA—Muscle spasms—Simvastatin—atherosclerosis	0.00125	0.00268	CcSEcCtD
L-DOPA—Angioedema—Ezetimibe—atherosclerosis	0.00124	0.00267	CcSEcCtD
L-DOPA—Leukopenia—Lovastatin—atherosclerosis	0.00124	0.00267	CcSEcCtD
L-DOPA—Malaise—Ezetimibe—atherosclerosis	0.00123	0.00264	CcSEcCtD
L-DOPA—Vision blurred—Simvastatin—atherosclerosis	0.00122	0.00263	CcSEcCtD
L-DOPA—Arrhythmia—Niacin—atherosclerosis	0.00122	0.00263	CcSEcCtD
L-DOPA—Tremor—Simvastatin—atherosclerosis	0.00121	0.00261	CcSEcCtD
L-DOPA—Alopecia—Niacin—atherosclerosis	0.00121	0.0026	CcSEcCtD
L-DOPA—Insomnia—Rosuvastatin—atherosclerosis	0.00121	0.0026	CcSEcCtD
L-DOPA—Ill-defined disorder—Simvastatin—atherosclerosis	0.0012	0.00259	CcSEcCtD
L-DOPA—Arrhythmia—Pravastatin—atherosclerosis	0.0012	0.00259	CcSEcCtD
L-DOPA—Palpitations—Ezetimibe—atherosclerosis	0.0012	0.00258	CcSEcCtD
L-DOPA—Paraesthesia—Rosuvastatin—atherosclerosis	0.0012	0.00258	CcSEcCtD
L-DOPA—Anaemia—Simvastatin—atherosclerosis	0.0012	0.00258	CcSEcCtD
L-DOPA—Alopecia—Pravastatin—atherosclerosis	0.00119	0.00256	CcSEcCtD
L-DOPA—Cough—Ezetimibe—atherosclerosis	0.00119	0.00255	CcSEcCtD
L-DOPA—Angioedema—Simvastatin—atherosclerosis	0.00118	0.00255	CcSEcCtD
L-DOPA—Chest pain—Lovastatin—atherosclerosis	0.00118	0.00254	CcSEcCtD
L-DOPA—Anxiety—Lovastatin—atherosclerosis	0.00118	0.00253	CcSEcCtD
L-DOPA—Dyspepsia—Rosuvastatin—atherosclerosis	0.00118	0.00253	CcSEcCtD
L-DOPA—Hypertension—Ezetimibe—atherosclerosis	0.00117	0.00253	CcSEcCtD
L-DOPA—Flatulence—Niacin—atherosclerosis	0.00117	0.00252	CcSEcCtD
L-DOPA—Malaise—Simvastatin—atherosclerosis	0.00117	0.00252	CcSEcCtD
L-DOPA—Tension—Niacin—atherosclerosis	0.00117	0.00251	CcSEcCtD
L-DOPA—Discomfort—Lovastatin—atherosclerosis	0.00117	0.00251	CcSEcCtD
L-DOPA—Leukopenia—Simvastatin—atherosclerosis	0.00116	0.0025	CcSEcCtD
L-DOPA—Chest pain—Ezetimibe—atherosclerosis	0.00116	0.00249	CcSEcCtD
L-DOPA—Nervousness—Niacin—atherosclerosis	0.00116	0.00249	CcSEcCtD
L-DOPA—Mesalazine—MPO—atherosclerosis	0.00116	0.0632	CrCbGaD
L-DOPA—Flatulence—Pravastatin—atherosclerosis	0.00116	0.00249	CcSEcCtD
L-DOPA—Dry mouth—Lovastatin—atherosclerosis	0.00115	0.00248	CcSEcCtD
L-DOPA—Tension—Pravastatin—atherosclerosis	0.00115	0.00247	CcSEcCtD
L-DOPA—Dysgeusia—Pravastatin—atherosclerosis	0.00115	0.00247	CcSEcCtD
L-DOPA—Muscle spasms—Niacin—atherosclerosis	0.00114	0.00246	CcSEcCtD
L-DOPA—Discomfort—Ezetimibe—atherosclerosis	0.00114	0.00246	CcSEcCtD
L-DOPA—Pain—Rosuvastatin—atherosclerosis	0.00114	0.00246	CcSEcCtD
L-DOPA—Constipation—Rosuvastatin—atherosclerosis	0.00114	0.00246	CcSEcCtD
L-DOPA—Confusional state—Lovastatin—atherosclerosis	0.00114	0.00245	CcSEcCtD
L-DOPA—Nervousness—Pravastatin—atherosclerosis	0.00114	0.00245	CcSEcCtD
L-DOPA—Dry mouth—Ezetimibe—atherosclerosis	0.00113	0.00244	CcSEcCtD
L-DOPA—Muscle spasms—Pravastatin—atherosclerosis	0.00113	0.00242	CcSEcCtD
L-DOPA—Vision blurred—Niacin—atherosclerosis	0.00112	0.00241	CcSEcCtD
L-DOPA—Confusional state—Ezetimibe—atherosclerosis	0.00112	0.00241	CcSEcCtD
L-DOPA—Thrombocytopenia—Lovastatin—atherosclerosis	0.00111	0.00238	CcSEcCtD
L-DOPA—Vision blurred—Pravastatin—atherosclerosis	0.0011	0.00238	CcSEcCtD
L-DOPA—Chest pain—Simvastatin—atherosclerosis	0.0011	0.00237	CcSEcCtD
L-DOPA—Feeling abnormal—Rosuvastatin—atherosclerosis	0.0011	0.00237	CcSEcCtD
L-DOPA—Anxiety—Simvastatin—atherosclerosis	0.0011	0.00237	CcSEcCtD
L-DOPA—Tremor—Pravastatin—atherosclerosis	0.0011	0.00236	CcSEcCtD
L-DOPA—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.00109	0.00235	CcSEcCtD
L-DOPA—Discomfort—Simvastatin—atherosclerosis	0.00109	0.00235	CcSEcCtD
L-DOPA—Angioedema—Niacin—atherosclerosis	0.00109	0.00234	CcSEcCtD
L-DOPA—Ill-defined disorder—Pravastatin—atherosclerosis	0.00109	0.00234	CcSEcCtD
L-DOPA—Thrombocytopenia—Ezetimibe—atherosclerosis	0.00109	0.00234	CcSEcCtD
L-DOPA—Anaemia—Pravastatin—atherosclerosis	0.00108	0.00233	CcSEcCtD
L-DOPA—Anorexia—Lovastatin—atherosclerosis	0.00108	0.00232	CcSEcCtD
L-DOPA—Angioedema—Pravastatin—atherosclerosis	0.00107	0.0023	CcSEcCtD
L-DOPA—Syncope—Niacin—atherosclerosis	0.00107	0.0023	CcSEcCtD
L-DOPA—Confusional state—Simvastatin—atherosclerosis	0.00107	0.0023	CcSEcCtD
L-DOPA—Leukopenia—Niacin—atherosclerosis	0.00107	0.00229	CcSEcCtD
L-DOPA—Urticaria—Rosuvastatin—atherosclerosis	0.00106	0.00228	CcSEcCtD
L-DOPA—Oedema—Simvastatin—atherosclerosis	0.00106	0.00228	CcSEcCtD
L-DOPA—Malaise—Pravastatin—atherosclerosis	0.00106	0.00227	CcSEcCtD
L-DOPA—Abdominal pain—Rosuvastatin—atherosclerosis	0.00106	0.00227	CcSEcCtD
L-DOPA—Palpitations—Niacin—atherosclerosis	0.00105	0.00226	CcSEcCtD
L-DOPA—Leukopenia—Pravastatin—atherosclerosis	0.00105	0.00226	CcSEcCtD
L-DOPA—Loss of consciousness—Niacin—atherosclerosis	0.00105	0.00225	CcSEcCtD
L-DOPA—Cough—Niacin—atherosclerosis	0.00104	0.00224	CcSEcCtD
L-DOPA—Thrombocytopenia—Simvastatin—atherosclerosis	0.00104	0.00223	CcSEcCtD
L-DOPA—Mesalazine—PPARG—atherosclerosis	0.00103	0.0561	CrCbGaD
L-DOPA—Insomnia—Lovastatin—atherosclerosis	0.00102	0.0022	CcSEcCtD
L-DOPA—Cough—Pravastatin—atherosclerosis	0.00102	0.0022	CcSEcCtD
L-DOPA—Paraesthesia—Lovastatin—atherosclerosis	0.00102	0.00219	CcSEcCtD
L-DOPA—Hypertension—Pravastatin—atherosclerosis	0.00101	0.00218	CcSEcCtD
L-DOPA—Anorexia—Simvastatin—atherosclerosis	0.00101	0.00217	CcSEcCtD
L-DOPA—Dyspnoea—Lovastatin—atherosclerosis	0.00101	0.00217	CcSEcCtD
L-DOPA—Insomnia—Ezetimibe—atherosclerosis	0.001	0.00216	CcSEcCtD
L-DOPA—Chest pain—Pravastatin—atherosclerosis	0.000998	0.00215	CcSEcCtD
L-DOPA—Paraesthesia—Ezetimibe—atherosclerosis	0.000996	0.00214	CcSEcCtD
L-DOPA—Dyspepsia—Lovastatin—atherosclerosis	0.000996	0.00214	CcSEcCtD
L-DOPA—Anxiety—Pravastatin—atherosclerosis	0.000995	0.00214	CcSEcCtD
L-DOPA—Dry mouth—Niacin—atherosclerosis	0.000991	0.00213	CcSEcCtD
L-DOPA—Dyspnoea—Ezetimibe—atherosclerosis	0.000989	0.00213	CcSEcCtD
L-DOPA—Discomfort—Pravastatin—atherosclerosis	0.000986	0.00212	CcSEcCtD
L-DOPA—Hypersensitivity—Rosuvastatin—atherosclerosis	0.000984	0.00212	CcSEcCtD
L-DOPA—Decreased appetite—Lovastatin—atherosclerosis	0.000984	0.00212	CcSEcCtD
L-DOPA—Dyspepsia—Ezetimibe—atherosclerosis	0.000977	0.0021	CcSEcCtD
L-DOPA—Fatigue—Lovastatin—atherosclerosis	0.000975	0.0021	CcSEcCtD
L-DOPA—Oedema—Niacin—atherosclerosis	0.000972	0.00209	CcSEcCtD
L-DOPA—Pain—Lovastatin—atherosclerosis	0.000968	0.00208	CcSEcCtD
L-DOPA—Constipation—Lovastatin—atherosclerosis	0.000968	0.00208	CcSEcCtD
L-DOPA—Confusional state—Pravastatin—atherosclerosis	0.000965	0.00208	CcSEcCtD
L-DOPA—Decreased appetite—Ezetimibe—atherosclerosis	0.000965	0.00208	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000958	0.00206	CcSEcCtD
L-DOPA—Asthenia—Rosuvastatin—atherosclerosis	0.000958	0.00206	CcSEcCtD
L-DOPA—Insomnia—Simvastatin—atherosclerosis	0.000957	0.00206	CcSEcCtD
L-DOPA—Oedema—Pravastatin—atherosclerosis	0.000957	0.00206	CcSEcCtD
L-DOPA—Fatigue—Ezetimibe—atherosclerosis	0.000957	0.00206	CcSEcCtD
L-DOPA—Shock—Niacin—atherosclerosis	0.000956	0.00206	CcSEcCtD
L-DOPA—Paraesthesia—Simvastatin—atherosclerosis	0.00095	0.00204	CcSEcCtD
L-DOPA—Pain—Ezetimibe—atherosclerosis	0.000949	0.00204	CcSEcCtD
L-DOPA—Constipation—Ezetimibe—atherosclerosis	0.000949	0.00204	CcSEcCtD
L-DOPA—Pruritus—Rosuvastatin—atherosclerosis	0.000945	0.00203	CcSEcCtD
L-DOPA—Dyspnoea—Simvastatin—atherosclerosis	0.000943	0.00203	CcSEcCtD
L-DOPA—Hyperhidrosis—Niacin—atherosclerosis	0.000939	0.00202	CcSEcCtD
L-DOPA—Thrombocytopenia—Pravastatin—atherosclerosis	0.000937	0.00202	CcSEcCtD
L-DOPA—Feeling abnormal—Lovastatin—atherosclerosis	0.000932	0.00201	CcSEcCtD
L-DOPA—Dyspepsia—Simvastatin—atherosclerosis	0.000932	0.002	CcSEcCtD
L-DOPA—Anorexia—Niacin—atherosclerosis	0.000926	0.00199	CcSEcCtD
L-DOPA—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000925	0.00199	CcSEcCtD
L-DOPA—Hyperhidrosis—Pravastatin—atherosclerosis	0.000925	0.00199	CcSEcCtD
L-DOPA—Decreased appetite—Simvastatin—atherosclerosis	0.00092	0.00198	CcSEcCtD
L-DOPA—Feeling abnormal—Ezetimibe—atherosclerosis	0.000914	0.00197	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000914	0.00197	CcSEcCtD
L-DOPA—Diarrhoea—Rosuvastatin—atherosclerosis	0.000913	0.00197	CcSEcCtD
L-DOPA—Fatigue—Simvastatin—atherosclerosis	0.000912	0.00196	CcSEcCtD
L-DOPA—Anorexia—Pravastatin—atherosclerosis	0.000912	0.00196	CcSEcCtD
L-DOPA—Hypotension—Niacin—atherosclerosis	0.000908	0.00195	CcSEcCtD
L-DOPA—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000907	0.00195	CcSEcCtD
L-DOPA—Pain—Simvastatin—atherosclerosis	0.000905	0.00195	CcSEcCtD
L-DOPA—Constipation—Simvastatin—atherosclerosis	0.000905	0.00195	CcSEcCtD
L-DOPA—Urticaria—Lovastatin—atherosclerosis	0.000899	0.00193	CcSEcCtD
L-DOPA—Abdominal pain—Lovastatin—atherosclerosis	0.000894	0.00192	CcSEcCtD
L-DOPA—Dizziness—Rosuvastatin—atherosclerosis	0.000883	0.0019	CcSEcCtD
L-DOPA—Urticaria—Ezetimibe—atherosclerosis	0.000882	0.0019	CcSEcCtD
L-DOPA—Insomnia—Niacin—atherosclerosis	0.000879	0.00189	CcSEcCtD
L-DOPA—Abdominal pain—Ezetimibe—atherosclerosis	0.000877	0.00189	CcSEcCtD
L-DOPA—Paraesthesia—Niacin—atherosclerosis	0.000873	0.00188	CcSEcCtD
L-DOPA—Feeling abnormal—Simvastatin—atherosclerosis	0.000872	0.00188	CcSEcCtD
L-DOPA—Dyspnoea—Niacin—atherosclerosis	0.000866	0.00186	CcSEcCtD
L-DOPA—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000865	0.00186	CcSEcCtD
L-DOPA—Insomnia—Pravastatin—atherosclerosis	0.000865	0.00186	CcSEcCtD
L-DOPA—Somnolence—Niacin—atherosclerosis	0.000864	0.00186	CcSEcCtD
L-DOPA—Paraesthesia—Pravastatin—atherosclerosis	0.000859	0.00185	CcSEcCtD
L-DOPA—Dyspepsia—Niacin—atherosclerosis	0.000855	0.00184	CcSEcCtD
L-DOPA—Dyspnoea—Pravastatin—atherosclerosis	0.000853	0.00184	CcSEcCtD
L-DOPA—Decreased appetite—Niacin—atherosclerosis	0.000845	0.00182	CcSEcCtD
L-DOPA—Dyspepsia—Pravastatin—atherosclerosis	0.000842	0.00181	CcSEcCtD
L-DOPA—Rash—Rosuvastatin—atherosclerosis	0.000842	0.00181	CcSEcCtD
L-DOPA—Dermatitis—Rosuvastatin—atherosclerosis	0.000841	0.00181	CcSEcCtD
L-DOPA—Urticaria—Simvastatin—atherosclerosis	0.000841	0.00181	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Niacin—atherosclerosis	0.000839	0.0018	CcSEcCtD
L-DOPA—Abdominal pain—Simvastatin—atherosclerosis	0.000837	0.0018	CcSEcCtD
L-DOPA—Headache—Rosuvastatin—atherosclerosis	0.000836	0.0018	CcSEcCtD
L-DOPA—Hypersensitivity—Lovastatin—atherosclerosis	0.000834	0.00179	CcSEcCtD
L-DOPA—Decreased appetite—Pravastatin—atherosclerosis	0.000832	0.00179	CcSEcCtD
L-DOPA—Pain—Niacin—atherosclerosis	0.000831	0.00179	CcSEcCtD
L-DOPA—Fatigue—Pravastatin—atherosclerosis	0.000825	0.00177	CcSEcCtD
L-DOPA—Pain—Pravastatin—atherosclerosis	0.000818	0.00176	CcSEcCtD
L-DOPA—Constipation—Pravastatin—atherosclerosis	0.000818	0.00176	CcSEcCtD
L-DOPA—Hypersensitivity—Ezetimibe—atherosclerosis	0.000818	0.00176	CcSEcCtD
L-DOPA—Asthenia—Lovastatin—atherosclerosis	0.000812	0.00175	CcSEcCtD
L-DOPA—Pruritus—Lovastatin—atherosclerosis	0.0008	0.00172	CcSEcCtD
L-DOPA—Asthenia—Ezetimibe—atherosclerosis	0.000796	0.00171	CcSEcCtD
L-DOPA—Gastrointestinal pain—Niacin—atherosclerosis	0.000795	0.00171	CcSEcCtD
L-DOPA—Nausea—Rosuvastatin—atherosclerosis	0.000793	0.00171	CcSEcCtD
L-DOPA—Feeling abnormal—Pravastatin—atherosclerosis	0.000788	0.0017	CcSEcCtD
L-DOPA—Pruritus—Ezetimibe—atherosclerosis	0.000785	0.00169	CcSEcCtD
L-DOPA—Gastrointestinal pain—Pravastatin—atherosclerosis	0.000782	0.00168	CcSEcCtD
L-DOPA—Hypersensitivity—Simvastatin—atherosclerosis	0.00078	0.00168	CcSEcCtD
L-DOPA—Diarrhoea—Lovastatin—atherosclerosis	0.000774	0.00167	CcSEcCtD
L-DOPA—Urticaria—Niacin—atherosclerosis	0.000772	0.00166	CcSEcCtD
L-DOPA—Abdominal pain—Niacin—atherosclerosis	0.000768	0.00165	CcSEcCtD
L-DOPA—Urticaria—Pravastatin—atherosclerosis	0.00076	0.00164	CcSEcCtD
L-DOPA—Asthenia—Simvastatin—atherosclerosis	0.000759	0.00163	CcSEcCtD
L-DOPA—Diarrhoea—Ezetimibe—atherosclerosis	0.000759	0.00163	CcSEcCtD
L-DOPA—Abdominal pain—Pravastatin—atherosclerosis	0.000756	0.00163	CcSEcCtD
L-DOPA—Pruritus—Simvastatin—atherosclerosis	0.000749	0.00161	CcSEcCtD
L-DOPA—Dizziness—Lovastatin—atherosclerosis	0.000748	0.00161	CcSEcCtD
L-DOPA—Dizziness—Ezetimibe—atherosclerosis	0.000734	0.00158	CcSEcCtD
L-DOPA—Diarrhoea—Simvastatin—atherosclerosis	0.000724	0.00156	CcSEcCtD
L-DOPA—Vomiting—Lovastatin—atherosclerosis	0.000719	0.00155	CcSEcCtD
L-DOPA—Hypersensitivity—Niacin—atherosclerosis	0.000716	0.00154	CcSEcCtD
L-DOPA—Rash—Lovastatin—atherosclerosis	0.000713	0.00153	CcSEcCtD
L-DOPA—Dermatitis—Lovastatin—atherosclerosis	0.000713	0.00153	CcSEcCtD
L-DOPA—Headache—Lovastatin—atherosclerosis	0.000709	0.00152	CcSEcCtD
L-DOPA—Vomiting—Ezetimibe—atherosclerosis	0.000706	0.00152	CcSEcCtD
L-DOPA—Hypersensitivity—Pravastatin—atherosclerosis	0.000705	0.00152	CcSEcCtD
L-DOPA—Dizziness—Simvastatin—atherosclerosis	0.0007	0.00151	CcSEcCtD
L-DOPA—Rash—Ezetimibe—atherosclerosis	0.0007	0.00151	CcSEcCtD
L-DOPA—Dermatitis—Ezetimibe—atherosclerosis	0.000699	0.0015	CcSEcCtD
L-DOPA—Asthenia—Niacin—atherosclerosis	0.000697	0.0015	CcSEcCtD
L-DOPA—Headache—Ezetimibe—atherosclerosis	0.000695	0.0015	CcSEcCtD
L-DOPA—Pruritus—Niacin—atherosclerosis	0.000687	0.00148	CcSEcCtD
L-DOPA—Asthenia—Pravastatin—atherosclerosis	0.000686	0.00148	CcSEcCtD
L-DOPA—Pruritus—Pravastatin—atherosclerosis	0.000677	0.00146	CcSEcCtD
L-DOPA—Vomiting—Simvastatin—atherosclerosis	0.000673	0.00145	CcSEcCtD
L-DOPA—Nausea—Lovastatin—atherosclerosis	0.000672	0.00145	CcSEcCtD
L-DOPA—Rash—Simvastatin—atherosclerosis	0.000667	0.00144	CcSEcCtD
L-DOPA—Dermatitis—Simvastatin—atherosclerosis	0.000667	0.00143	CcSEcCtD
L-DOPA—Diarrhoea—Niacin—atherosclerosis	0.000665	0.00143	CcSEcCtD
L-DOPA—Headache—Simvastatin—atherosclerosis	0.000663	0.00143	CcSEcCtD
L-DOPA—Nausea—Ezetimibe—atherosclerosis	0.000659	0.00142	CcSEcCtD
L-DOPA—Diarrhoea—Pravastatin—atherosclerosis	0.000655	0.00141	CcSEcCtD
L-DOPA—Dizziness—Niacin—atherosclerosis	0.000643	0.00138	CcSEcCtD
L-DOPA—Dizziness—Pravastatin—atherosclerosis	0.000633	0.00136	CcSEcCtD
L-DOPA—Nausea—Simvastatin—atherosclerosis	0.000629	0.00135	CcSEcCtD
L-DOPA—Vomiting—Niacin—atherosclerosis	0.000618	0.00133	CcSEcCtD
L-DOPA—Rash—Niacin—atherosclerosis	0.000613	0.00132	CcSEcCtD
L-DOPA—Dermatitis—Niacin—atherosclerosis	0.000612	0.00132	CcSEcCtD
L-DOPA—Headache—Niacin—atherosclerosis	0.000609	0.00131	CcSEcCtD
L-DOPA—Vomiting—Pravastatin—atherosclerosis	0.000608	0.00131	CcSEcCtD
L-DOPA—Rash—Pravastatin—atherosclerosis	0.000603	0.0013	CcSEcCtD
L-DOPA—Dermatitis—Pravastatin—atherosclerosis	0.000603	0.0013	CcSEcCtD
L-DOPA—Headache—Pravastatin—atherosclerosis	0.000599	0.00129	CcSEcCtD
L-DOPA—Nausea—Niacin—atherosclerosis	0.000577	0.00124	CcSEcCtD
L-DOPA—Nausea—Pravastatin—atherosclerosis	0.000568	0.00122	CcSEcCtD
L-DOPA—Aminosalicylic Acid—PTGS2—atherosclerosis	0.000552	0.0302	CrCbGaD
L-DOPA—Epinephrine—TNF—atherosclerosis	0.000525	0.0287	CrCbGaD
L-DOPA—Mesalazine—PTGS2—atherosclerosis	0.000433	0.0237	CrCbGaD
L-DOPA—Liothyronine—ALB—atherosclerosis	0.000332	0.0182	CrCbGaD
L-DOPA—DRD5—Signaling Pathways—LEP—atherosclerosis	4.05e-05	0.000146	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CAV1—atherosclerosis	4.01e-05	0.000144	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—APOA1—atherosclerosis	4e-05	0.000144	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SOCS3—atherosclerosis	4e-05	0.000144	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PRKCG—atherosclerosis	3.99e-05	0.000143	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VWF—atherosclerosis	3.97e-05	0.000143	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOC3—atherosclerosis	3.95e-05	0.000142	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—KNG1—atherosclerosis	3.93e-05	0.000141	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—LDLR—atherosclerosis	3.92e-05	0.000141	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AGTR1—atherosclerosis	3.9e-05	0.00014	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—KNG1—atherosclerosis	3.87e-05	0.000139	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—ESR1—atherosclerosis	3.87e-05	0.000139	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AGT—atherosclerosis	3.86e-05	0.000139	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP3—atherosclerosis	3.86e-05	0.000139	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CYP27A1—atherosclerosis	3.86e-05	0.000139	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AGTR1—atherosclerosis	3.85e-05	0.000138	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF2—atherosclerosis	3.85e-05	0.000138	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL3—atherosclerosis	3.83e-05	0.000138	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCL2—atherosclerosis	3.83e-05	0.000138	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—F2—atherosclerosis	3.82e-05	0.000137	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PLG—atherosclerosis	3.8e-05	0.000137	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCL2—atherosclerosis	3.78e-05	0.000136	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PLG—atherosclerosis	3.75e-05	0.000135	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APOB—atherosclerosis	3.73e-05	0.000134	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CXCL8—atherosclerosis	3.7e-05	0.000133	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—EDN1—atherosclerosis	3.67e-05	0.000132	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NCF1—atherosclerosis	3.67e-05	0.000132	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOA2—atherosclerosis	3.66e-05	0.000131	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PLA2G2A—atherosclerosis	3.66e-05	0.000131	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALOX5AP—atherosclerosis	3.66e-05	0.000131	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALOX15—atherosclerosis	3.66e-05	0.000131	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PIK3CG—atherosclerosis	3.65e-05	0.000131	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL5—atherosclerosis	3.65e-05	0.000131	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ABCG5—atherosclerosis	3.61e-05	0.00013	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SOCS3—atherosclerosis	3.6e-05	0.000129	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—F2—atherosclerosis	3.57e-05	0.000128	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—LPL—atherosclerosis	3.57e-05	0.000128	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SOCS3—atherosclerosis	3.55e-05	0.000128	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AGT—atherosclerosis	3.51e-05	0.000126	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—MAPK3—atherosclerosis	3.5e-05	0.000126	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—LPA—atherosclerosis	3.49e-05	0.000125	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP3—atherosclerosis	3.48e-05	0.000125	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PRKCG—atherosclerosis	3.47e-05	0.000125	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EDNRA—atherosclerosis	3.46e-05	0.000125	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCR2—atherosclerosis	3.46e-05	0.000125	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF2—atherosclerosis	3.46e-05	0.000124	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—INS—atherosclerosis	3.46e-05	0.000124	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CYBA—atherosclerosis	3.45e-05	0.000124	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP3—atherosclerosis	3.43e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PIK3CG—atherosclerosis	3.42e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF2—atherosclerosis	3.42e-05	0.000123	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCL2—atherosclerosis	3.4e-05	0.000122	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—BGN—atherosclerosis	3.38e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SPP1—atherosclerosis	3.38e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PARP1—atherosclerosis	3.38e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PLAT—atherosclerosis	3.38e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GHRL—atherosclerosis	3.38e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCL8—atherosclerosis	3.36e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOB—atherosclerosis	3.36e-05	0.000121	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IGF1—atherosclerosis	3.35e-05	0.00012	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOA5—atherosclerosis	3.34e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCL8—atherosclerosis	3.33e-05	0.00012	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOB—atherosclerosis	3.32e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—EDN1—atherosclerosis	3.31e-05	0.000119	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCL8—atherosclerosis	3.29e-05	0.000118	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL5—atherosclerosis	3.28e-05	0.000118	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—EDN1—atherosclerosis	3.26e-05	0.000117	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—F2—atherosclerosis	3.24e-05	0.000117	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL5—atherosclerosis	3.24e-05	0.000116	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PLA2G1B—atherosclerosis	3.22e-05	0.000116	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—LPL—atherosclerosis	3.21e-05	0.000115	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SERPINE1—atherosclerosis	3.18e-05	0.000114	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—LPL—atherosclerosis	3.17e-05	0.000114	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PDGFB—atherosclerosis	3.12e-05	0.000112	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PRKCG—atherosclerosis	3.12e-05	0.000112	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALOX5—atherosclerosis	3.11e-05	0.000112	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PIK3CG—atherosclerosis	3.1e-05	0.000112	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PRKCG—atherosclerosis	3.08e-05	0.000111	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AGT—atherosclerosis	3.05e-05	0.00011	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SPP1—atherosclerosis	3.04e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NOS3—atherosclerosis	3.03e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCL8—atherosclerosis	3.03e-05	0.000109	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SPP1—atherosclerosis	3e-05	0.000108	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APOE—atherosclerosis	2.99e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—LEP—atherosclerosis	2.99e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCL8—atherosclerosis	2.99e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—KNG1—atherosclerosis	2.96e-05	0.000107	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CAV1—atherosclerosis	2.96e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—APOA1—atherosclerosis	2.95e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AGTR1—atherosclerosis	2.95e-05	0.000106	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCL2—atherosclerosis	2.89e-05	0.000104	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PLG—atherosclerosis	2.87e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ESR1—atherosclerosis	2.85e-05	0.000103	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—F2—atherosclerosis	2.82e-05	0.000101	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PDGFB—atherosclerosis	2.81e-05	0.000101	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NAMPT—atherosclerosis	2.79e-05	0.0001	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PDGFB—atherosclerosis	2.78e-05	9.98e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—LIPC—atherosclerosis	2.77e-05	9.96e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOC3—atherosclerosis	2.75e-05	9.9e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AGT—atherosclerosis	2.75e-05	9.87e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—LDLR—atherosclerosis	2.74e-05	9.84e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SOCS3—atherosclerosis	2.72e-05	9.77e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AGT—atherosclerosis	2.71e-05	9.74e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PIK3CG—atherosclerosis	2.7e-05	9.7e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL8—atherosclerosis	2.69e-05	9.67e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—LEP—atherosclerosis	2.69e-05	9.67e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOE—atherosclerosis	2.69e-05	9.67e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CETP—atherosclerosis	2.67e-05	9.61e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CAV1—atherosclerosis	2.67e-05	9.58e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—APOA1—atherosclerosis	2.66e-05	9.56e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—LEP—atherosclerosis	2.65e-05	9.54e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOE—atherosclerosis	2.65e-05	9.54e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CAV1—atherosclerosis	2.63e-05	9.46e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP3—atherosclerosis	2.63e-05	9.44e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—APOA1—atherosclerosis	2.62e-05	9.43e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF2—atherosclerosis	2.61e-05	9.4e-05	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—AKT1—atherosclerosis	2.6e-05	9.35e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—MAPK3—atherosclerosis	2.58e-05	9.29e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ESR1—atherosclerosis	2.57e-05	9.23e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—SCARB1—atherosclerosis	2.56e-05	9.2e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL6—atherosclerosis	2.56e-05	9.2e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—INS—atherosclerosis	2.55e-05	9.18e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOB—atherosclerosis	2.54e-05	9.12e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—F2—atherosclerosis	2.54e-05	9.12e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ESR1—atherosclerosis	2.53e-05	9.11e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL8—atherosclerosis	2.52e-05	9.05e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCL2—atherosclerosis	2.51e-05	9.03e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—F2—atherosclerosis	2.5e-05	9e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—EDN1—atherosclerosis	2.5e-05	8.98e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL5—atherosclerosis	2.48e-05	8.91e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IGF1—atherosclerosis	2.47e-05	8.88e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MMP9—atherosclerosis	2.43e-05	8.75e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PIK3CG—atherosclerosis	2.43e-05	8.73e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—LPL—atherosclerosis	2.42e-05	8.71e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HMGCR—atherosclerosis	2.42e-05	8.69e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—NFKB1—atherosclerosis	2.41e-05	8.66e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PIK3CG—atherosclerosis	2.4e-05	8.61e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK8—atherosclerosis	2.37e-05	8.51e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—AKT1—atherosclerosis	2.36e-05	8.49e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PRKCG—atherosclerosis	2.36e-05	8.47e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SERPINE1—atherosclerosis	2.34e-05	8.43e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—MAPK3—atherosclerosis	2.33e-05	8.36e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—INS—atherosclerosis	2.3e-05	8.26e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SPP1—atherosclerosis	2.3e-05	8.25e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—MAPK3—atherosclerosis	2.29e-05	8.25e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL8—atherosclerosis	2.28e-05	8.22e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—INS—atherosclerosis	2.27e-05	8.15e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCL2—atherosclerosis	2.26e-05	8.13e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NOS3—atherosclerosis	2.24e-05	8.05e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCL2—atherosclerosis	2.23e-05	8.02e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IGF1—atherosclerosis	2.22e-05	7.99e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IGF1—atherosclerosis	2.19e-05	7.89e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—VEGFA—atherosclerosis	2.19e-05	7.86e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STAT3—atherosclerosis	2.16e-05	7.78e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ABCA1—atherosclerosis	2.15e-05	7.75e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PDGFB—atherosclerosis	2.12e-05	7.63e-05	CbGpPWpGaD
L-DOPA—DDC—Metabolism—AKT1—atherosclerosis	2.12e-05	7.63e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SERPINE1—atherosclerosis	2.11e-05	7.59e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SERPINE1—atherosclerosis	2.08e-05	7.49e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AGT—atherosclerosis	2.07e-05	7.45e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—MAPK3—atherosclerosis	2.07e-05	7.43e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOE—atherosclerosis	2.03e-05	7.3e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—LEP—atherosclerosis	2.03e-05	7.3e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NOS3—atherosclerosis	2.02e-05	7.25e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CAV1—atherosclerosis	2.01e-05	7.24e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—APOA1—atherosclerosis	2.01e-05	7.22e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TGFB1—atherosclerosis	2.01e-05	7.21e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NOS3—atherosclerosis	1.99e-05	7.15e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL8—atherosclerosis	1.99e-05	7.14e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ESR1—atherosclerosis	1.94e-05	6.97e-05	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—AKT1—atherosclerosis	1.92e-05	6.9e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—F2—atherosclerosis	1.92e-05	6.89e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—atherosclerosis	1.89e-05	6.79e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—HMOX1—atherosclerosis	1.85e-05	6.65e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PIK3CG—atherosclerosis	1.83e-05	6.59e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MMP9—atherosclerosis	1.8e-05	6.46e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL8—atherosclerosis	1.79e-05	6.43e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—NFKB1—atherosclerosis	1.78e-05	6.39e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOB—atherosclerosis	1.77e-05	6.37e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL8—atherosclerosis	1.76e-05	6.34e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—MAPK3—atherosclerosis	1.76e-05	6.31e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK8—atherosclerosis	1.75e-05	6.28e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—AKT1—atherosclerosis	1.74e-05	6.26e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—INS—atherosclerosis	1.74e-05	6.24e-05	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—AKT1—atherosclerosis	1.73e-05	6.21e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GSTM1—atherosclerosis	1.72e-05	6.19e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCL2—atherosclerosis	1.71e-05	6.14e-05	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—AKT1—atherosclerosis	1.7e-05	6.13e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—atherosclerosis	1.7e-05	6.11e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—LPL—atherosclerosis	1.69e-05	6.08e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IGF1—atherosclerosis	1.68e-05	6.03e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—atherosclerosis	1.68e-05	6.03e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GPX1—atherosclerosis	1.65e-05	5.93e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MMP9—atherosclerosis	1.62e-05	5.81e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—VEGFA—atherosclerosis	1.61e-05	5.8e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CD36—atherosclerosis	1.61e-05	5.77e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—NFKB1—atherosclerosis	1.6e-05	5.75e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STAT3—atherosclerosis	1.6e-05	5.74e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MMP9—atherosclerosis	1.6e-05	5.74e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SERPINE1—atherosclerosis	1.59e-05	5.73e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—NFKB1—atherosclerosis	1.58e-05	5.68e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK8—atherosclerosis	1.57e-05	5.65e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—AKT1—atherosclerosis	1.57e-05	5.64e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK8—atherosclerosis	1.55e-05	5.58e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—AKT1—atherosclerosis	1.55e-05	5.56e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MAPK3—atherosclerosis	1.53e-05	5.49e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MTHFR—atherosclerosis	1.52e-05	5.47e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NOS3—atherosclerosis	1.52e-05	5.47e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—atherosclerosis	1.51e-05	5.43e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARA—atherosclerosis	1.49e-05	5.37e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TGFB1—atherosclerosis	1.48e-05	5.32e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—VEGFA—atherosclerosis	1.45e-05	5.22e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AGT—atherosclerosis	1.45e-05	5.2e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STAT3—atherosclerosis	1.44e-05	5.17e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—VEGFA—atherosclerosis	1.43e-05	5.15e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STAT3—atherosclerosis	1.42e-05	5.1e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOE—atherosclerosis	1.42e-05	5.09e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—CAV1—atherosclerosis	1.4e-05	5.05e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—APOA1—atherosclerosis	1.4e-05	5.04e-05	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—AKT1—atherosclerosis	1.39e-05	5.01e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MAPK3—atherosclerosis	1.37e-05	4.94e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MAPK3—atherosclerosis	1.36e-05	4.87e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL8—atherosclerosis	1.35e-05	4.85e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TGFB1—atherosclerosis	1.33e-05	4.79e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TGFB1—atherosclerosis	1.31e-05	4.73e-05	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—AKT1—atherosclerosis	1.3e-05	4.69e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—atherosclerosis	1.28e-05	4.61e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PIK3CG—atherosclerosis	1.28e-05	4.6e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PPARG—atherosclerosis	1.23e-05	4.44e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MMP9—atherosclerosis	1.22e-05	4.39e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—INS—atherosclerosis	1.21e-05	4.35e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—NFKB1—atherosclerosis	1.21e-05	4.34e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK8—atherosclerosis	1.19e-05	4.27e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—AKT1—atherosclerosis	1.18e-05	4.26e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—atherosclerosis	1.12e-05	4.01e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALB—atherosclerosis	1.11e-05	3.99e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—VEGFA—atherosclerosis	1.1e-05	3.94e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STAT3—atherosclerosis	1.09e-05	3.9e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—NOS3—atherosclerosis	1.06e-05	3.82e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MAPK3—atherosclerosis	1.04e-05	3.73e-05	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—AKT1—atherosclerosis	1.03e-05	3.7e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TGFB1—atherosclerosis	1.01e-05	3.62e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—atherosclerosis	1e-05	3.61e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—atherosclerosis	9.91e-06	3.56e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—atherosclerosis	9.71e-06	3.49e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—AKT1—atherosclerosis	9.26e-06	3.33e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—AKT1—atherosclerosis	9.14e-06	3.29e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—atherosclerosis	7.58e-06	2.73e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—AKT1—atherosclerosis	6.99e-06	2.51e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—AKT1—atherosclerosis	4.88e-06	1.75e-05	CbGpPWpGaD
